PDE9A
High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A
As of the edition of 20 October 2026, PDE9A (high affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A, UniProt O76083) has 4 drugs tested at it and 5 companies on the list, 4 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- O76083
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 25
- Disease areas
- Mental health; Nervous system; Heart and blood vessels; Blood and lymph; Inherited and neonatal
- Registered trials of its drugs
- 45
Drugs at this target
| Status | Count |
|---|---|
| Active | 1 |
| Stopped | 3 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Osoresnontrine | Stopped | Phase 2 | none listed |
| Edelinontrine | Stopped | Phase 2 | none listed |
| Tovinontrine | Stopped | Phase 2 | none listed |
| Irsenontrine | Active | Phase 2 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 4 |
| Engaged | 1 |
| Total on the list | 5 |
| Company | Route |
|---|---|
| Pfizer | Route A |
| Boehringer Ingelheim | Route A |
| Cardurion Pharmaceuticals | Route A |
The other 2 companies at PDE9A
In the product5 companies in all; 2 are not named here, and no score is.
See the 5 companies at PDE9A, ranked, with the facts behind eachRequest access. Nothing is shown until you do.